康华生物(300841) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 355,615,965.41, a decrease of 9.92% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 120,733,207.85, down 27.98% year-on-year[5]. - Basic earnings per share decreased by 27.84% to CNY 0.9027[5]. - Total operating revenue for Q3 2023 was CNY 990,055,021.87, a decrease of 6.1% compared to CNY 1,054,548,588.74 in Q3 2022[25]. - Net profit for Q3 2023 was CNY 368,938,090.47, down 23.6% from CNY 483,313,059.38 in Q3 2022[26]. - Total comprehensive income for the third quarter was CNY 368,938,090.47, down from CNY 483,313,059.38 in the previous year, representing a decrease of approximately 23.6%[27]. - Basic earnings per share decreased to CNY 2.7584 from CNY 3.6067, reflecting a decline of about 23.5%[27]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,915,121,263.82, an increase of 5.50% from the end of the previous year[5]. - Total assets as of Q3 2023 amounted to CNY 3,915,121,263.82, up from CNY 3,711,065,217.69 at the end of Q3 2022[24]. - Total liabilities decreased to CNY 536,180,760.82 from CNY 635,397,264.58 in the previous year, reflecting a reduction of 15.6%[24]. - The company’s equity attributable to shareholders increased to CNY 3,378,940,503.00, up from CNY 3,075,667,953.11, representing an increase of 9.8%[24]. Cash Flow - The net cash flow from operating activities surged by 1,250.24% to CNY 265,007,516.70 year-to-date[15]. - Cash flow from operating activities increased to CNY 1,009,078,054.00, compared to CNY 725,750,505.53 in the previous year, marking an increase of approximately 38.9%[28]. - Net cash flow from operating activities was CNY 265,007,516.70, significantly up from CNY 19,626,743.71 in the same period last year[28]. - Cash flow from investing activities showed a net outflow of CNY 111,993,981.88, an improvement from a net outflow of CNY 300,268,331.23 in the previous year[28]. - Cash flow from financing activities resulted in a net outflow of CNY 53,949,194.47, compared to a net outflow of CNY 63,744,091.42 in the previous year, indicating a reduction in cash outflow[28]. Research and Development - Research and development expenses increased by 45.56% to CNY 185,927,273.77 year-to-date[12]. - Research and development expenses rose to CNY 185,927,273.77, an increase of 45.5% compared to CNY 127,730,120.19 in the same period last year[25]. - The company has a strong focus on research and development for new products and technologies, aiming to enhance its market position[22]. Shareholder Information - The total number of unrestricted shares held by the top 10 shareholders includes 21,705,468 shares held by Aokang Group Co., Ltd., representing a significant portion of the company's equity[19]. - The company reported a total of 16,309,028 restricted shares at the end of the period, down from 16,697,088 at the beginning of the year, indicating a reduction in restricted shares[21]. Future Outlook - Future outlook includes plans for market expansion and potential mergers and acquisitions to drive growth[22]. - The company maintains a robust financial position with a significant increase in liquid assets, positioning itself well for future investments and strategic initiatives[22]. Other Information - The company experienced a significant increase in long-term deferred expenses by 132.46% to CNY 124,965,967.39 due to increased renovation costs[10]. - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous year[27]. - The company has not undergone an audit for the third quarter report[29]. - The report was released by the board of directors on October 21, 2023[30].